Polarityte (NASDAQ: COOL) is one of 192 public companies in the “Prepackaged software” industry, but how does it compare to its competitors? We will compare Polarityte to related businesses based on the strength of its valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
This is a summary of recent ratings and price targets for Polarityte and its competitors, as reported by MarketBeat.
||Strong Buy Ratings
Polarityte currently has a consensus price target of $65.00, indicating a potential upside of 275.07%. As a group, “Prepackaged software” companies have a potential upside of 0.73%. Given Polarityte’s stronger consensus rating and higher possible upside, analysts plainly believe Polarityte is more favorable than its competitors.
Earnings and Valuation
This table compares Polarityte and its competitors revenue, earnings per share and valuation.
Polarityte’s competitors have higher revenue and earnings than Polarityte. Polarityte is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Polarityte has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Polarityte’s competitors have a beta of -19.85, suggesting that their average stock price is 2,085% less volatile than the S&P 500.
Insider and Institutional Ownership
43.1% of Polarityte shares are owned by institutional investors. Comparatively, 58.4% of shares of all “Prepackaged software” companies are owned by institutional investors. 43.3% of Polarityte shares are owned by company insiders. Comparatively, 21.7% of shares of all “Prepackaged software” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Polarityte and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Polarityte beats its competitors on 8 of the 13 factors compared.
PolarityTE, Inc. engages in the regenerative medicine and tissue engineering platform. The firm seeks to develop and obtain regulatory approval for technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. Its products include SkinTE, OsteoTE, AngioTE, MyoTE, CartTe, AdiposeTE, and NeuralTE. The company was founded in 2004 and is headquartered in Salt Lake City, UT.
Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.